EDWARDS JEFFREY L 4

What Happened

• Jeffrey L. Edwards, a director of Bio‑Rad Laboratories (BIO), reported transactions dated 2026-04-21. He exercised/converted 407 derivative securities (code M) resulting in an acquisition and an immediate disposition of 407 shares, each reported at $0.00. He was also granted 369 restricted stock units (RSUs) (code A) reported at $0.00. The filing shows $0 cash exchanged for these reported transactions.

Key Details

• Transaction date: 2026-04-21; Form 4 filed: 2026-04-23 (appears timely).
• Exercise/conversion (M): 407 shares acquired @ $0.00 and 407 shares disposed @ $0.00 (same date).
• Grant/award (A): 369 RSUs granted @ $0.00 (reported as a derivative).
• Footnotes:
  • F1: Shares acquired on the vesting of RSUs.
  • F2: Each RSU represents a contingent right to one share of Bio‑Rad Class A common stock.
  • F3: The RSUs will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting.
• Shares owned after the reported transactions: Not specified in the provided filing excerpt.
• No late‑filing flag was indicated in the data you provided.

Context

• Code M indicates exercise/conversion of a derivative security; here that resulted in acquisition and immediate disposition of the same number of shares. The filing does not state the reason for the disposition (e.g., sale vs. tax withholding).
• The 369 RSUs are contingent awards (not immediately transferable stock) and will vest per the schedule in footnote F3.
• These entries are administrative/compensation-related transactions rather than open‑market purchases; they do not by themselves indicate a change in personal investment conviction.